Selective and reversible inhibitors of ubiquitin-specific protease 7: a patent evaluation (WO2013030218)

Bibliography

• Clague MJ, Urbe S. Ubiquitin: same molecule, different degradation pathways. Cell 2010;143(5):682-5
   PubMed Web of Science ®Google Scholar
• Komander D, Rape M. The ubiquitin code. Annu Rev Biochem 2012;81:203-29
   PubMed Web of Science ®Google Scholar
• Kulathu Y, Komander D. Atypical ubiquitylation - the unexplored world of polyubiquitin beyond Lys48 and Lys63 linkages. Nat Rev Mol Cell Biol 2012;13(8):508-23
   PubMed Web of Science ®Google Scholar
• Katz EJ, Isasa M, Crosas B. A new map to understand deubiquitination. Biochem Soc Trans 2010;38(Pt 1):21-8
   PubMed Web of Science ®Google Scholar
• Nijman SM, Luna-Vargas MP, Velds A, et al. A genomic and functional inventory of deubiquitinating enzymes. Cell 2005;123(5):773-86
   PubMed Web of Science ®Google Scholar
• Nicholson B, Suresh Kumar KG. The multifaceted roles of USP7; new therapeutic opportunities. Cell Biochem Biophys 2011;60(1-2):61-8
   PubMed Web of Science ®Google Scholar
• Colland F, Formstecher E, Jacq X, et al. Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells. Mol Cancer Ther 2009;8(8):2286-95
   PubMed Web of Science ®Google Scholar
• Nicholson B, Marblestone JG, Butt TR, Mattern MR. Deubiquitinating enzymes as novel anticancer targets. Future Oncol 2007;3(2):191-9
   PubMedGoogle Scholar
• Edelmann MJ, Nicholson B, Kessler BM. Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases. Expert Rev Mol Med 2011;13:e35
   PubMed Web of Science ®Google Scholar
• Colland F. The therapeutic potential of deubiquitinating enzyme inhibitors. Biochem Soc Trans 2010;38(Pt 1):137-43
   PubMed Web of Science ®Google Scholar
• van Loosdregt J, Fleskens V, Fu J, et al. Stabilization of the transcription factor Foxp3 by the deubiquitinase USP7 increases Treg-cell-suppressive capacity. Immunity 2013;39(2):259-71
   PubMed Web of Science ®Google Scholar
• Holowaty MN, Sheng Y, Nguyen T, et al. Protein interaction domains of the ubiquitin-specific protease, USP7/HAUSP. J Biol Chem 2003;278(48):47753-61
   PubMed Web of Science ®Google Scholar
• Jacq X, Kemp M, Martin NM, Jackson SP. Deubiquitylating enzymes and DNA damage response pathways. Cell Biochem Biophys 2013;67(1):25-43
   PubMed Web of Science ®Google Scholar
• Gao Y, Koppen A, Rakhshandehroo M, et al. Early adipogenesis is regulated through USP7-mediated deubiquitination of the histone acetyltransferase TIP60. Nat Commun 2013;4:2656
   PubMed Web of Science ®Google Scholar
• Chauhan D, Tian Z, Nicholson B, et al. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell 2012;22(3):345-58
   PubMed Web of Science ®Google Scholar
• Fan YH, Cheng J, Vasudevan SA, et al. USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis. Cell Death Dis 2013;4:e867
   PubMed Web of Science ®Google Scholar
• Colleran A, Collins PE, O’Carroll C, et al. Deubiquitination of NF-kappaB by Ubiquitin-Specific Protease-7 promotes transcription. Proc Natl Acad Sci USA 2013;110(2):618-23
   PubMed Web of Science ®Google Scholar
• Cao P, Weinstock J, Kingsbury WD, et al. Anti-neoplastic compounds, compositions and methods. WO2010114881 A1(PCT/US2010/029358): US20120114765; 2010
   Google Scholar
• Carmody RJ. Treatment of inflammation. WO2012056048 A1(PCT/EP2011/069171): EP2446883A1; 2012
   Google Scholar
• Colland F, Gourdel M-E. Selective and reversible inhibitors of ubiquitin specific protease 7. WO2013030218 A1(PCT/EP2012/066741):EP2565186A1, WO2013030218A4; 2013
   Google Scholar
• Reverdy C, Conrath S, Lopez R, et al. Discovery of specific inhibitors of human USP7/HAUSP deubiquitinating enzyme. Chem Biol 2012;19(4):467-77
   PubMedGoogle Scholar
• Colombo M, Vallese S, Peretto I, et al. Synthesis and biological evaluation of 9-oxo-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile analogues as potential inhibitors of deubiquitinating enzymes. ChemMedChem 2010;5(4):552-8
   PubMed Web of Science ®Google Scholar
• Lopez R, Colland F. Amidoacridine derivatives useful as selective inhibitors of ubiquitin specific protease 7. WO2011086178 A1(PCT/EP2011/050523): CA2786957A1, CN102781919A, EP2357176A1, EP2523938A1, US20110177105, US30023521; 2011
   Google Scholar
• Lopez R, Collura V, Sippl W, Colland F. Novel specific inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications. WO2010081783 A1(PCT/EP2010/050223): EP2208725A1; 2010
   Google Scholar
• Altun M, Kramer HB, Willems LI, et al. Activity-based chemical proteomics accelerates inhibitor development for deubiquitylating enzymes. Chem Biol 2011;18(11):1401-12
   PubMedGoogle Scholar
• Tian X, Sh Isamiddinova N, Peroutka RJ, et al. Characterization of selective ubiquitin and ubiquitin-like protease inhibitors using a fluorescence-based multiplex assay format. Assay Drug Dev Technol 2011;9(2):165-73
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Miyazaki M, Kodrasov MP, et al. Spongiacidin C, a pyrrole alkaloid from the marine sponge Stylissa massa, functions as a USP7 inhibitor. Bioorg Med Chem Lett 2013;23(13):3884-6
   PubMed Web of Science ®Google Scholar
• Weinstock J, Wu J, Cao P, et al. Selective dual inhibitors of the cancer-related deubiquitylating proteases USP7 and USP47. ACS Med Chem Lett 2012;3(10):789-92
   PubMed Web of Science ®Google Scholar
• Dar A, Shibata E, Dutta A. Deubiquitination of Tip60 by USP7 determines the activity of the p53-dependent apoptotic pathway. Mol Cell Biol 2013;33(16):3309-20
   PubMed Web of Science ®Google Scholar
• FORMA Therapeutics and CRT to discover cancer drugs targeting deubiquitinating enzymes (DUBs). Cancer Res Technol 2013; Available from: http://www.cancerresearchuk.org/about-us/cancer-news/press-release/forma-therapeutics-and-cancer-research-technology-to-discover-cancer-drugs-targeting
   Google Scholar
• Delivering highly innovative cancer therapeutics targeting ubiquitin pathways involved in the DNA damage response. Mission Ther 2013; Available from: http://www.missiontherapeutics.com
   Google Scholar